Education
About Us
Working with TipRanks
Follow Us
IGC Pharma (IGC)
:IGC
IGC Stock Chart & Stats
$0.30
>-$0.01(-2.38%)
At close: 4:00 PM EST
$0.30
>-$0.01(-2.38%)
Day’s Range― - ―
52-Week Range$0.25 - $0.50
Previous CloseN/A
Volume646.33K
Average Volume (3M)715.71K
Market Cap
$28.14M
Enterprise Value$22.89M
Total Cash (Recent Filing)$1.10M
Total Debt (Recent Filing)$137.00K
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Feb 18, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding92,868,240
10 Day Avg. Volume826,885
30 Day Avg. Volume715,709
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)3.45
Price to Sales (P/S)17.16
P/FCF Ratio-4.13
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue20.69
Enterprise Value/Gross Profit44.79
Enterprise Value/Ebitda-3.55
Forecast
1Y Price Target
$4.75Price Target Upside1483.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsIGC reported positive interim results from its Phase 2 trial for IGC-AD1, showing a significant reduction in agitation compared to placebo in patients with Alzheimer's disease.
Growth OpportunitiesThe company's strategic expansion into the $75 billion wellness industry with the launch of the Holiby brand offers new growth opportunities.
Market PotentialThe large market potential for Alzheimer's treatments presents high rewards despite the risks, given the growing number of Americans affected by the disease.
Bears Say
Market RisksThe large market potential for Alzheimer's disease treatment, due to the absence of a known cure and a growing number of patients, presents high rewards for the risks involved.
IGC Pharma News
IGC FAQ
What was IGC Pharma’s price range in the past 12 months?
IGC Pharma lowest stock price was $0.25 and its highest was $0.50 in the past 12 months.
What is IGC Pharma’s market cap?
IGC Pharma’s market cap is $28.14M.
When is IGC Pharma’s upcoming earnings report date?
IGC Pharma’s upcoming earnings report date is Feb 18, 2026 which is in 54 days.
How were IGC Pharma’s earnings last quarter?
IGC Pharma released its earnings results on Nov 17, 2025. The company reported -$0.02 earnings per share for the quarter, the consensus estimate of -$0.02 by $0.
Is IGC Pharma overvalued?
According to Wall Street analysts IGC Pharma’s price is currently Undervalued.
Does IGC Pharma pay dividends?
IGC Pharma does not currently pay dividends.
What is IGC Pharma’s EPS estimate?
IGC Pharma’s EPS estimate is -0.02.
How many shares outstanding does IGC Pharma have?
IGC Pharma has 92,868,240 shares outstanding.
What happened to IGC Pharma’s price movement after its last earnings report?
IGC Pharma reported an EPS of -$0.02 in its last earnings report, expectations of -$0.02. Following the earnings report the stock price went down -5.556%.
Which hedge fund is a major shareholder of IGC Pharma?
Currently, no hedge funds are holding shares in IGC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
IGC Pharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.75 (1483.33% Upside)
$4.75 (1483.33% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.8%
Last 30 Days ▼ 9.1%
Last 30 Days ▼ 9.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.25%
12-Months-Change
Fundamentals
Return on Equity
-83.34%
Trailing 12-Months
Asset Growth
-25.02%
Trailing 12-Months
Company Description
IGC Pharma
IGC Pharma (IGC) is a biopharmaceutical company focused on developing innovative therapies for the treatment of various medical conditions, including neurological disorders and pain management. The company operates within the pharmaceutical sector, leveraging its proprietary technology platform to create cannabinoid-based formulations. IGC's core products include therapeutics that aim to address significant unmet medical needs, particularly in the areas of mental health and chronic pain.
IGC Earnings Call
Q2 2025
0:00 / 0:00
IGC Stock 12 Month Forecast
Average Price Target
$4.75
▲(1483.33% Upside)
Technical Analysis
Ownership Overview
7.66% Insiders
1.40% Mutual Funds
0.30% Other Institutional Investors
89.87% Public Companies and
Individual Investors